- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc stock price live, this page displays NASDAQ RXRX stock exchange data. View the RXRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Recursion Pharmaceuticals Inc real time stock price chart below.
What Is the Recursion Pharmaceuticals Inc Stock Price Today?
The Recursion Pharmaceuticals Inc stock price today is 6.26.
What Is the Stock Symbol for Recursion Pharmaceuticals Inc?
The stock symbol for Recursion Pharmaceuticals Inc is ""RXRX.""
What Stock Exchange Does Recursion Pharmaceuticals Inc Trade On?
Recursion Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Recursion Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Recursion Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RXRX quote. (ISIN: US75629V1044)
What Is the Recursion Pharmaceuticals Inc Stock Price Today?
The Recursion Pharmaceuticals Inc stock price today is 6.26.
What Is the Stock Symbol for Recursion Pharmaceuticals Inc?
The stock symbol for Recursion Pharmaceuticals Inc is ""RXRX.""
What Stock Exchange Does Recursion Pharmaceuticals Inc Trade On?
Recursion Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Recursion Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Recursion Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RXRX quote. (ISIN: US75629V1044)
NASDAQ
Currency in USD
6.26
-0.17(-2.64%)
Closed·
After Hours
6.22-0.04(-0.64%)
·
Fair Value
An estimate of a Recursion Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.25
6.56
52 wk Range
3.79
12.36
RXRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RXRX is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Recursion Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.256.56
52 wk Range
3.7912.36
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RXRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Recursion Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
6.67
Upside
+6.50%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
- Form 8K Recursion Pharmaceuticals Inc For: 8 July
- Investing.com
- Form 8K Recursion Pharmaceuticals Inc For: 8 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Recursion Pharmaceuticals Inc Company Profile
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Recursion Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Q1 2025 results: EPS -$0.5 vs -$0.49 forecast, revenue $14.75M vs $14.98M expected; stock down 4.04% premarket
- Strong cash position of $509M ensures operations through mid-2027; reduced operational cash burn to $118M in Q1
- Company anticipates key clinical readouts and new studies in 2025-2026; revenue projected to grow 26% in FY2025
- Merger with Excientia streamlines operations; focus on high-potential programs and strategic partnerships
- Analysts revise earnings downward; stock near 52-week low, but trading close to fair value per InvestingPro analysis
Last Updated: 05/05/2025, 14:16
Read Full TranscriptCompare RXRX to Peers and Sector
Metrics to compare | RXRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRXRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.7x | −1.6x | −0.5x | |
PEG Ratio | 0.39 | −0.01 | 0.00 | |
Price/Book | 2.9x | 0.8x | 2.6x | |
Price / LTM Sales | 45.4x | 8.6x | 3.2x | |
Upside (Analyst Target) | 1.1% | 153.2% | 41.9% | |
Fair Value Upside | Unlock | 26.2% | 4.3% | Unlock |
Analyst Ratings
2 Buy
6 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 6.67
(+6.50% Upside)
Earnings
Latest Release
May 05, 2025
EPS / Forecast
-0.50 / -0.49
Revenue / Forecast
14.75M / 14.98M
People Also Watch
FAQ
What Stock Exchange Does Recursion Pharmaceuticals Trade On?
Recursion Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Recursion Pharmaceuticals?
The stock symbol for Recursion Pharmaceuticals is "RXRX."
What Is the Recursion Pharmaceuticals Market Cap?
As of today, Recursion Pharmaceuticals market cap is 2.73B.
What Is Recursion Pharmaceuticals's Earnings Per Share (TTM)?
The Recursion Pharmaceuticals EPS (TTM) is -1.82.
When Is the Next Recursion Pharmaceuticals Earnings Date?
Recursion Pharmaceuticals will release its next earnings report on 11 Aug 2025.
From a Technical Analysis Perspective, Is RXRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Recursion Pharmaceuticals Stock Split?
Recursion Pharmaceuticals has split 0 times.
How Many Employees Does Recursion Pharmaceuticals Have?
Recursion Pharmaceuticals has 800 employees.
What is the current trading status of Recursion Pharmaceuticals (RXRX)?
As of 24 Jul 2025, Recursion Pharmaceuticals (RXRX) is trading at a price of 6.26, with a previous close of 6.43. The stock has fluctuated within a day range of 6.25 to 6.56, while its 52-week range spans from 3.79 to 12.36.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.